Swedish biotechnology company Cantargia AB (STO:CANTA) announced on Thursday a positive opinion from European authorities for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer.
The positive opinion from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) was based on data from the ongoing CANFOUR trial, a phase I/IIa study in which CAN04 is being investigated in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as first-line combination with gemcitabine and nab-paclitaxel.
The European Commission is now expected to grant the orphan designation within 30 days.
CAN04 was granted orphan drug designation for treatment of pancreatic cancer by the US Food and Drug Administration (FDA) in September 2021.
An interleukin-1 receptor accessory protein (IL1RAP)-binding antibody, CAN04 is currently being investigated in multiple clinical trials evaluating combination with chemotherapy regimens in various forms of cancer, including PDAC, the most common form of pancreatic cancer.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial